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Abstract: Cervical screening in low-resource settings remains an unmet need. Lectins are naturally
occurring sugar-binding glycoproteins whose binding patterns change as cancer develops. Lectins
discriminate between dysplasia and normal tissue in several precancerous conditions. We explored
whether lectins could be developed for cervical screening via visual inspection. Discovery work
comprised lectin histochemistry using a panel of candidate lectins on fixed-human cervix tissue
(high-grade cervical intraepithelial neoplasia (CIN3, n = 20) or normal (n = 20)), followed by validation
in a separate cohort (30 normal, 25 CIN1, 25 CIN3). Lectin binding was assessed visually according
to staining intensity. To validate findings macroscopically, near-infra red fluorescence imaging
was conducted on freshly-resected cervix (1 normal, 7 CIN3), incubated with topically applied
fluorescently-labelled lectin. Fluorescence signal was compared for biopsies and whole specimens
according to regions of interest, identified by the overlay of histopathology grids. Lectin histochemistry
identified two lectins—wheat germ agglutinin (WGA) and Helix pomatia agglutinin (HPA)—with
significantly decreased binding to CIN3 versus normal in both discovery and validation cohorts.
Findings at the macroscopic level confirmed weaker WGA binding (lower signal intensity) in CIN3
vs. normal for biopsies (p = 0.0308) and within whole specimens (p = 0.0312). Our findings confirm
proof-of-principle and indicate that WGA could potentially be developed further as a probe for
high-grade cervical disease.
Keywords: lectins; cervical cancer; screening; glycans
Cancers 2020, 12, 1928; doi:10.3390/cancers12071928 www.mdpi.com/journal/cancers
Cancers 2020, 12, 1928 2 of 15
1. Introduction
Cervical cancer remains the most common female malignancy in many developing countries [1]
where high-quality organised screening has not been possible [2]. Of the ~570,000 women diagnosed
each year globally, over half will die from the disease—88% of these deaths occur in developing
countries [1]. Cervical screening involves detecting and treating high-grade cervical intraepithelial
neoplasia (CIN grade 2 or worse, CIN2+) to prevent cancer from developing. Due to financial constraints
and limited infrastructure, many low resource countries favour cervical screening via visual inspection
(with acetic acid (VIA) and/or Lugol’s iodine (VILI), topically applied to the cervix making high-grade
disease visible) [3]. Visual inspection enables women to be seen and treated at the same visit but has
much room for improvement due to its low specificity (14–98%) and variable sensitivity (41–98%) to
detect CIN2+ [4,5]. Given the heavy and disproportionate burden of disease in developing countries,
there is a need to identify a specific, reproducible and affordable imaging method that can be used for
cervical screening in low-resource settings. In particular, there is a need for visualization methods to
identify precursor lesions on the cervix.
Lectins are naturally occurring glycoproteins of non-immune origin which bind to sugars (glycans)
on the surface of cells [6]. Their ubiquity throughout nature means that they are widely available and
can be produced at low cost. The neoplastic transformation of cells is associated with changes in cell
surface glycoconjugates [7,8] and alterations in lectin binding with dysplasia or carcinogenesis have
been observed in numerous organs (e.g., oesophagus [9], pancreas [10], skin [11,12], bladder [13,14],
colon [15], stomach [16–18] and cervix [19]). Aberrant sialylation and fucosylation have also been
described as early markers of cervical carcinogenesis [20]. There is compelling evidence that topically
applied fluorescently labelled lectins can identify areas of dysplasia. WGA binding decreases with
increasing dysplasia in Barrett’s oesophagus (a premalignant state of oesophageal adenocarcinoma) [9,21],
colorectal dysplasia [22] and oral dysplasia and malignancy [23–26]. In cervical cancer, markedly reduced
sialylation was found in the glycoproteins of malignant tissue [20].
The aim of this study was to act as a proof-of-principle study to explore whether fluorescently-labelled
lectins, topically applied to the cervix, show potential to be developed as a form of cervical screening
in low-resource settings. This lectins-based approach to cervical screening would comprise real-time
visual assessment using wide-field fluorescence imaging, fluorescence-enhanced colposcopy or wide-field
fluorescence imaging, based on a fluorescence-capable light source (e.g., torch) [27,28]. Wheat germ
agglutinin (WGA) demonstrated an ability to discriminate normal tissue from high-grade CIN at both the
microscopic (lectin histochemistry on formalin-fixed paraffin-embedded (FFPE) tissue) and, to a limited
extent, the macroscopic level (near-infrared (NIR) fluorescence imaging of conjugated lectins topically
applied to freshly resected human cervix). This exploratory work warrants further in vivo studies with
WGA to further explore its potential in cervical screening.
2. Results
2.1. Discovery Lectin Histochemistry
Eleven candidate lectins were identified by a literature search and by the previous work in Barrett’s
oesophagus [9]. Of these, eight were successfully optimised and taken forward for lectin histochemistry.
Lectin staining was significantly less intense in 20 CIN3 slides compared with 20 slides of normal
squamous epithelium tissue for three of the eight candidate lectins: Wheat germ agglutinin (WGA)
(p < 0.0001); Helix pomatia agglutinin (HPA) (p = 0.0002); Urea europaeus agglutinin (UEA) (p = 0.007).
Representative examples of lectin staining for these and corresponding lectin staining scores are shown
in Figure 1a,b.
For UEA, the absolute staining intensity was weak (median score of 1 in normal cervical tissue,
where staining intensity was scored on an arbitrary scale: 0 = no stain; 1 = weak stain; 2 = moderate
stain; 3 = strong stain).
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Figure 1. Lectin histochemistry for the discovery cohort for the three lectins which showed 
significantly weaker staining in CIN3 vs. normal human FFPE cervical tissue: WGA, HPA and UEA. 
(a) Representative examples of lectin histochemistry (brown). (b) Lectin staining scores (based on 
visual assessment) for (n = 20) normal versus (n = 20) CIN3 human FFPE cervical tissue samples for 
WGA, HPA and UEA. 
2.2. Validation of Lectin Histochemistry 
Validation was undertaken for WGA and HPA (the best discriminators of dysplasia during the 
discovery phase) in a separate cohort of FFPE samples (30 normal, 25 CIN1, 25 CIN3). UEA was not 
taken forward for validation due to the weak absolute staining intensity in the discovery phase, 
indicating it would not be useful as a visual assessment tool. As with the discovery cohort, lectin 
staining was weaker in CIN3 versus normal tissue for both WGA (p = 0.0044) and HPA (p = 0.0002). 
However, the differences in staining intensity were less marked than in the discovery cohort—
median scores of 0 (CIN3) and 2.75 (normal) versus 1 (CIN3) and 2 (normal) for WGA and HPA, 
respectively. 
The staining of CIN1 was similar to normal tissue but more intense than the staining of CIN3 
with HPA (p = 0.0008), but not with WGA (p = 0.6943). Lectin staining scores for WGA and HPA for 
normal cervix, CIN1 and CIN3, are shown in Figure 2. 
Figure 1. Lectin histochemistry for the discovery cohort for the three lectins which showed significantly
weaker staining in CIN3 vs. normal human FFPE cervical tissue: WGA, HPA and UEA. (a) Representative
examples of lectin histochemistry (brown). (b) Lectin staining scores (based on visual assessment) for
(n = 20) normal versus (n = 20) CIN3 human FFPE cervical tissue samples for WGA, HPA and UEA.
2.2. Validation of Lectin Histochemistry
ation was undertak n for WGA and HPA (the best discriminators of dysplasia during the
discovery phase) in a separate cohort of FFPE samples (30 normal, 25 CIN1, 25 CIN3). UEA was not taken
forward for validation due to the weak absolute staining intensity in the discovery phase, indicating it
would not be useful as a visual assessment tool. As with the discovery cohort, lectin staining was weaker
in CIN3 versus normal tissue for both WGA (p = 0.0044) and HP (p = 0.0002). However, the differences
in staining intensity were less marked than in the discovery cohort—median scores of 0 (CIN3) and 2.75
(normal) versus 1 (CIN3) and 2 (normal) for WGA and HPA, respectively.
The taining of 1 was similar to normal tissue but more intense than the staining of CIN3
with HPA (p = 0.0008), but not with WGA (p = 0.6943). Lectin staining scores for WGA and HPA for
normal cervix, CIN1 and CIN3, are show in Figure 2.
Within specimen comparisons of lectin, staining was also performed for normal tissue adjacent to
CIN1 and CIN3. The staining of normal tissue adjacent to CIN was consistently stronger than CIN3
(WGA p = 0.0487, HPA p = 0.0001) and CIN1 (WGA p = 0.0023 and HPA p = 0.0028).
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Overall concordance for inter-rater agreement for lectin staining for discovery and validation was
86.7% (kappa 0.65 (95%CI 0.60–0.67), p < 0.0001).
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Figure 2. Frequency (%) of lectin histochemistry visual intensity staining scores for WGA and HPA for
normal cervix, CIN1 and CIN3 human FFPE tissue in the validation coh rt.
Lectin Histochemistry Sensitivity and Specificity for CIN3
In order to further assess the discri inatory power of lectin histochemistry to discern CIN3 from
normal cervix, we calculated sensitivity and specificity using a staining score threshold of 0/1 = “positive”
and 2/3 = “negative”. In the discovery cohort, WGA dem nstrated the highest discriminatory power
with a sensitivit of 75% (15/20) (95%CI 50.9–91.3), a specificity of 85% (17/20) (95%CI 62.1–96.8) and an
Area Under the Curve (AUC) of 0.884 (95%CI 78.2–98.5). For HPA, sensitivity was 70% (14/20) (95%CI
45.7–88.1), specificity was 8 % (16/20) (95%CI 56.3–94.2) and AUC was 0.843 (95%CI 0.710–0.976), and for
UEA, sensitivity was 85% (17/20) (95%CI 62.1–96.8), specificity was 40% (8/20) (95%CI 1 .1–63.9) and AUC
was 0.796 (95%CI 0.660–0.932).
In the validation cohort, the sensitivity and specificity ere lower in comparison to the discovery
cohort for both lectins. WGA sensitivity was 60% (15/25) (95%CI 38.7–78.9), specificity was 87% (26/30)
(95%CI 69.3- 96.2), and AUC was 0.708 (95%CI 0.566–0.850), while HPA sensitivity was 84% (21/25)
(95%CI 63.9–95.5), specificity was 69% (20/29) (95%CI 49.2–84.7) and AUC was 0.792 (95%CI 0.661–0.922).
Figure 3 shows the corresponding Receiver–Operator Characteristic (ROC) curves for discovery and
validation cohorts.
2.3. Molecular Imaging of Topically Applied Fluorescently-Labelled Lectin to Freshly Resected Human Cervix
Only WGA was taken forward for ex vivo studies of molecular imaging. The decision to not take
HPA forward was mainly based on the favourable existing data on WGA in Barrett’s oesophagus [9]
and colorectal cancer [21]. Additionally, HPA is derived from the Burgundy snail, which is known to be
an allergen [29], limiting its potential as a topical agent. Other lectins have been used as histochemical
reagents for sialic detection (e.g., GS-II, TJA, SNA, MAL) [30]. However, their reduced availability and
potential toxicity make them less viable as candidates for topical imaging applications in comparison
with WGA, which is derived from edible wheat germ, a dietary constituent. Freshly resected cervix
tissue samples were obtained from nine women. Two samples were pinned incorrectly (i.e., ectocervix
facing down), leaving a total of seven samples that were analysable (1 normal and 6 CIN3). From these,
22 biopsies were taken, of which 14 were analysable—normal (n = 10) and CIN3 (n = 4). Excluded biopsies
comprised samples from two women (4 biopsies from each). One had a large transformation zone and
none of the biopsies contained tissue relevant for analysis (i.e., no normal squamous epithelium or
CIN3, endocervical/metaplastic epithelium only) and, in the other sample, the biopsies were embedded
incorrectly, hence histopathology could not be read.
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cohort (WGA: 30 normal, 25 CIN3, HPA WGA: 29 normal, 25 CIN3) ROC curves showing comparatively
weaker discriminatory power for both WGA and HPA.
2.3.1. Whole Specimens
Pairwise (within sample) analysis of regions of interest (ROI) within six whole specimens, as shown
in Table 1 (patients 104–110), found a significant difference in the mean MFI (p = 0.0312) between
regions of CIN3 and regions of normal tissue.
Table 1. Summary of freshly-resected whole-specimen human cervix samples for ex vivo molecular
imaging using fluorescently-labelled WGA lectin.
Patient Number Age (Years)
Pathological
Diagnosis
Mean Fluorescent Intensity MFI (SD)
Contrast (%) 1 Dysplasia,% of AreaNormal CIN3
101 53 Normal 0.111 (0.009) N/E N/D 0
104 38 CIN3 0.119 (0.008) 0.090 (0.008) 24.6 4.8
105 44 CIN3 0.063 (0.006) 0.0584 (0.004) 7.6 26.7
106 42 CIN3 0.184 (0.021) 0.146 (0.030) 20.8 18.6
107 28 CIN3 0.048 (0.006) 0.038 (0.007) 21.7 10.1
108 25 CIN3 0.153 (0.055) 0.115 (0.039) 24.8 49.3
110 25 CIN3 0.224 (0.073) 0.180 (0.055) 19.5 33.2
1 Defined as (MFICIN3–MFInormal)/MFInormal × 100 (%); N/D, not defined; N/E, non-existent.
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2.3.2. Biopsies
The comparison of signal intensity for all 14 biopsies from the whole specimens, according to the
histology (of the biopsy), showed that WGA binding was significantly lower in CIN3 versus normal
biopsies; mean MFI 0.066 (±0.011) vs. 0.104 (±0.033), respectively (t (13.89) = 3.37, p= 0.0046).
The final two samples collected were specifically targeted as they had large and demarcated areas
of CIN3 (on colposcopic impression) with large areas of surrounding normal tissue. These samples
were analysed whole, with no biopsies collected. One of the specimens had a particularly large area of
CIN3 with normal surrounding squamous epithelial tissue, as shown in Figure 4. In this specimen,
WGA binding appeared to be weaker in the CIN3 area, as demonstrated by lower fluorescence signal.
Figure 4e shows that the large area of CIN3 appeared substantially darker (less fluorescence) in the
ROI compared with the surrounding normal tissue.Cancers 2020, 12, x 8 of 15 
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Figure 4. Images of a freshly resected human cervical specimen incubated with fluorescently-labelled
WGA, which was selected for having a large area of CIN3 (top) surrounded by normal squamous
epithelial tissue (lower). This specimen showed clear discrimination between CIN3 and normal
squamous tissue. (a) White light image of the specimen; (b) specimen overlaid with histopathology grid
with a crisscrossed pattern indicating a large area of CIN3 (top); (c) NIR fluorescence image displayed
in pseudo-colour scale; (d) NIR fluorescence image of the same specimen which showed that the area
of CIN3 has low fluorescence; (e) overlay image of the NIR fluorescent image with the corresponding
pathology grid; (f) NIR fluorescence image (greyscale) showing that the lowest fluorescent signal
intensity (ROI 1; top) is seen in the area of CIN3. Scale bar is 1 cm.
i exploratory study has demonstra ed proof- f-principle that topically applied fluorescently-labelled
WGA lectin could potentially be developed as an imaging probe for real-time cervical screening using wide
field fluoresce ce imaging. Lectin histo he istry in the discovery cohor was particularly promising and
showed the remarkable bility f lectins WGA and HPA to discriminate CIN3 from normal quamous
epitheliu . The findings were conf rmed in the validation cohort but wer less distinct for reasons that are
uncl ar. Validation at the macroscopic leve ex vivo were also positive. In a ool d analysis of biopsies
fluorescently label , WGA binding was ignificantly lower (lower signal intensity) for CIN3 versus normal
tissu ex vivo. Similarl , signal intensity for regions of int r st within whole specimens showed significantly
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lower signal from CIN3 compared to normal tissue (n = 6, p = 0.0312). On lectin histochemistry CIN1
staining was less intense than CIN3 for HPA but was similar for WGA.
It is encouraging that WGA was identified as having the highest discriminatory power from the
panel of lectins, given that this is the same lectin that has been shown to identify dysplasia in other
precancerous conditions involving epithelial tissue [9,21,22]. WGA was able to consistently delineate areas
of high grade disease within the same specimen, as shown in Table 1, albeit with low contrast. The latter
ability was reassuring as this most closely replicates the clinical scenario in which lectins would be used
for cervical cancer screening (i.e., topically applied lectin followed by biopsy of suspected CIN3 based
on visualization of signal intensity). The extent of contrast obtained might have been affected by field
effects and specimen quality. Most of the CIN3 samples collected had only very small areas of CIN3,
which tended to be within the crypts and therefore did not lend themselves well to visual assessment.
Surrounding areas of tissue were also often suboptimal with a large transformation zone and/or cervical
ectopy leaving little to no normal squamous epithelium for comparison. Nevertheless, results from the
validation cohort were promising and validated observations from the discovery cohort.
Key limitations of our study are the small number of samples included and the intrinsically
imprecise co-registration of histopathology with fluorescent images acquired from fresh specimens.
Although the co-registration of histopathology grids with fluorescent images by image overlay is prone
to error, this is, nevertheless, a suitable approach for exploratory studies [21]. Similarly, the scoring
for the lectin histology staining in the discovery cohort was based on subjective visual assessment.
As mentioned above, the qualities of most of the ex vivo specimens collected were suboptimal for
our chosen method of visual assessment and may explain the results. In well-screened populations
(such as England), cervical disease with large areas of CIN3 are rare, thus suitable samples were
difficult to obtain.
In previous studies of lectin histochemistry in FFPE human cervical tissue, Griffonia simplicifolia
II was the only lectin from a panel of nine which showed significantly different binding patterns
between normal and CIN, but no difference was found using WGA [31,32]. These studies, however,
were performed with a majority of specimens containing CIN 1–2. Our findings are in accord with
other studies using fluorescently-labelled WGA in the gastrointestinal tract, which demonstrated the
lower binding of WGA with increasing grades of dysplasia [9,22]. Similarly, in Barrett’s oesophagus,
WGA showed decreased binding in dysplastic versus non-dysplastic areas in ex vivo studies [9,21].
WGA-IR800 was able to identify dysplasia at the whole specimen level in freshly collected endoscopic
mucosal resections in both pooled analyses across specimens and within specimen analyses [21].
Aberrant glycosylation has been explored as a biomarker for carcinogenesis in several cancers [7].
One of the most advanced lectin probes in terms of clinical translation is a chairside optimal
imaging system using WGA-fluorescein isothiocyanate (FITC) with a handheld light to detect oral
malignancies [23,24]. Baeten et al. [23] found that topically applied WGA-FITC to oral mucosa in vivo
had a sensitivity of 89% (95% CI 73–96%) and specificity of 82% (95% CI 62–93%) for detecting oral
dysplasia and cancer. This model in oral cancer is highly relevant to the future development of lectins
as a probe for cervical screening, given that both malignancies arise in squamous epithelium and
are particularly prevalent in developing countries in sub-Saharan Africa and South East Asia [33,34].
Furthermore, a handheld light device is likely to be easily translated into cervical screening for
low-resource settings where lightweight mobile equipment is desirable [35].
Currently, the majority of tools being developed for cervical screening in low resource settings remain
focused on improving “see-and-treat” approaches (i.e., real time visualization of disease) [27,36,37].
Such approaches can be used either for primary screening or for triage of HPV positive women. A key
advantage of “see-and-treat” cervical screening modalities is that women can be screened and treated
(i.e., CIN2+ removed by excision or cautery) at the same visit. Digital cervicography [38] and other forms
of digital imaging, such as smartphone-based images (often combined with machine-learning) [36,39,40],
are being developed as either improvements or adjuncts to “see-and-treat” approaches. The emerging
field of smartphone fluorescence microscopy [28] aligns well with these developments and with our
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proposed approach. Our early exploratory data warrant further studies of WGA to see if it can be
successfully developed as an imaging biomarker for “see-and-treat” early cervical cancer screening.
WGA has binding specificity for terminally installed sialic acid residues on tissue glycoproteins. [20,41].
Moreover, cervical cancer has lower levels of sialylation in comparison with healthy cervix [41], and,
therefore, the potential for a fluorescently-labelled version of the lectin to be used topically as an early
diagnostic imaging probe is worthy of further investigation. Even if the discriminatory ability shown
in the small number cohort analysed is lower than hoped, potentially, a lectin probe could be used in
conjunction with VIA and/or VILI (and have a role in helping to define whether high grade disease is
present (after first defining an area of interest using acetic acid/Lugol’s iodine).
A further potential application of lectins in cervical screening is in colposcopy. The main goals of
colposcopy are to identify areas most likely to be high grade CIN (for diagnostic biopsy) and to identify
areas of CIN (in women with confirmed high-grade CIN) for excisional or destructive treatment.
Acetic acid and Lugol’s iodine are used in situ to identify cervical neoplasia for diagnostic biopsy.
The accuracy of colposcopically-guided biopsy has been criticised for its low sensitivity for detecting
CIN grade 2 or worse [42–44]. An imaging probe with higher sensitivity and adequate specificity for
detecting high grade CIN than acetic acid and Lugol’s iodine remains an unmet clinical need.
4. Materials and Methods
4.1. Human Tissue
Lectin histochemistry was performed on 120 formalin fixed paraffin embedded (FFPE) cervical
tissue samples. Ethical approval was obtained from the South West Wales REC (13/WA/0151). All samples
were provided anonymously from a tissue bank of diagnostic specimens at the Barts Health NHS Trust,
London, UK. Ten sections (5 µm thick) were cut from each tissue block and mounted onto slides for
staining. The fifth section from each set was stained with haematoxylin and eosin (H&E). An independent
histopathologist (S.L.S.L.) confirmed the clinical diagnosis and marked out areas of dysplasia on the
H&E sections of CIN1 and CIN3 samples. Forty samples were used for the discovery work—20 normal
and 20 CIN3 samples. Eighty samples were included for the validation work—30 normal, 25 CIN1 and
25 CIN3. Samples were derived from tissue that had been removed in the previous 5 years, from women
aged between 25 and 59 years at the time of resection.
For the molecular imaging of lectin staining, ethical approval was granted from the Yorkshire
and the Humber–Bradford Leeds Research Ethics Committee (15/YH/0371). Freshly resected cervix
tissue was prospectively collected from nine women for treatment purposes from a single secondary
care centre between January 2016 and June 2017. Written informed consent was obtained from all
participants. Normal cervical tissue comprised surplus surgical tissue from hysterectomies performed
for non-cervical indications (e.g., fibroids, endometriosis). During the study, two “normal” cervix tissue
samples were collected; however, an unexpected finding of a small area of CIN3 was identified during
histopathology reading on one of the samples. This sample was reclassified into the CIN3 group for
analysis. Seven high-grade CIN tissue samples were collected from women undergoing excisional
treatment (knife cone or loop biopsies) for confirmed CIN3 on previous biopsy. Participants had a
mean age of 39.7 years (range, 25–73 years), (normal age range 53–73, CIN3 age range 25–44 years).
The first seven samples collected had only small areas of CIN3 (often within the crypts and not on the
surface) and very little surrounding normal squamous epithelial tissue for comparison (due to large
transformation zones and/or ectropions). Therefore, for the final two samples, we specifically targeted
women with large areas of CIN3 on colposcopy, and without an ectropion or large transformation zone.
4.2. Pathological Diagnosis
Histopathological assessment for all specimens was carried out (independently of fluorescence
staining) at Barts Health NHS Trust (Royal London Hospital, London). For each cervix sample,
the specimen was photographed and dissected by a histopathologist (S.L.S.L. or N.S.), and then
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correlated with the H&E stained sections to map the areas of normal squamous epithelium and
areas of CIN3 onto the photograph to produce a “histopathology grid”. For lectin histochemistry,
N.S. and S.L.S.L. examined the H&E stained sections to determine histology. A single independent
histopathologist (either S.L.S.L. or N.S.) examined the slides for the fluorescently-labelled lectin samples.
4.3. Identification of Candidate Lectins
A panel of 11 candidate lectins were identified for initial screening. Eight [31,32,45–59] were
identified via a literature search: Concanavalin ensiformis (ConA) [31,49,52,54,60]; Griffonia simplicifolia II
(GS II) [31,32,59]; Vicia villosa agglutinin (VVA) [51]; Artocarpus integrifolia-Jack fruit lectin (JFL) [55,57,58];
Sambucus nigra (SNA) [53]; Maackia amurensis (MAA) [53]; Ulex europaeus I (UEA I) [31,32,45,47,48];
Dolichos Biflorus agglutinin (DBA) [52,59]. The other three lectins were those which best identified
dysplasia in Barrett’s oesophagus [9]: Triticum vulgaris (wheat germ agglutinin (WGA)); Helix pomatia
agglutinin (HPA); Aspergillus oryzae lectin (AOL) [9].
4.4. Lectin Histochemistry
For the discovery work, lectin histochemistry was performed using eight candidate lectins (DBA,
Con A and MAA could not be optimised (no real positivity)) on FFPE samples (20 normal and 20 CIN3).
Validation was undertaken in a separate cohort of biopsies (30 normal, 25 CIN1 and 25 CIN3) for WGA
and HPA.
Slides were de-paraffinized by immersion in xylene (2× 2 min), followed by immersion in decreasing
concentrations of ethanol (96%, 75%, and 50%) (× 5 min), and washed in water (2 × 5 min) then lectin
buffer (20 mM HEPES, 150 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, pH 7.4) (1 × 5 min). Slides were
then placed in a humidified incubation chamber and 5 µg/mL lectin (labelled with biotin) was applied,
followed by incubation at 37% for 15 min. Unbound lectin was washed off by immersion in running
water (2 × 30 min), and mounted with Prolong Gold antifade reagent with DAPI (Invitrogen, Paisley,
UK). Biotin labelled lectin was visualised with the standard Avidin–Biotin Complex (ABC) method with
a complex of avidin–biotin peroxidase. The peroxidase was then developed by 3,3’ diaminobenzidine
(DAB) to produce different colorimetric end products.
4.4.1. Scoring
For the discovery work, two researchers (including at least one histopathologist, N.S., S.L.S.L.
and P.L.S.) independently scored the top third of squamous epithelium for the intensity of lectin
staining. A histopathologist (M.S.) adjudicated when there was disagreement. Each section was scored
for staining intensity on an arbitrary scale: 0 = no stain; 1 = weak stain; 2 = moderate stain; 3 = strong
stain. For sections from normal cervix a score for the entire section was taken. For sections with CIN3,
an average of scores across all areas of CIN3 was calculated. Additionally, areas of normal tissue on
CIN3 sections were scored within section comparisons of normal versus CIN3 lectin staining.
Concordance for inter-rater agreement was calculated for lectin staining scores with the associated
weighted kappa statistic.
4.4.2. Sensitivity and Specificity to High Grade Cervical Disease
The sensitivity and specificity of CIN3 for lectin histochemistry staining was calculated for lectins,
which showed discriminatory power using a threshold score of 0/1 = positive and ≥2 = negative.
4.5. Molecular Imaging of Fluorescently-Labelled Lectin
4.5.1. Staining Protocol
Samples were transported at 2–8 ◦C (on wet ice and/or cool packs) to a clinic in Cambridge
University Hospitals NHS Foundation Trust, where each cervical specimen was pinned under an
open-field fluorescent imaging camera (Fluobeam® 800 CE Mark, Fluoptics, Grenoble, France),
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sprayed with fluorescein-labelled WGA (WGA-IR800CW, was prepared as described previously [21])
and incubated by immersion in lectin solution (10 ug/mL in PBS buffer) for up to 15 min at room
temperature. The tissue was then washed three times with excess cold PBS buffer (to remove any excess
unbound lectin) and imaged using near-infrared fluorescent (NIR) and visible light.
Using NIR fluorescence as a guide, up to four biopsies (4 mm diameter) were collected from each
specimen (one from each quadrant, using a disposable skin biopsy punch device). From CIN3 samples,
two were collected from regions of lowest fluorescent signal intensity (i.e., suspected dysplasia) and
two from the highest intensity regions (i.e., expected to be normal). The researchers collecting the
biopsies were guided purely by visual impression of signal intensity and had no prior knowledge
of where the areas of CIN3 were located. For normal samples, four punch biopsies were taken from
random areas in the transformation zone of the cervix (one from each quadrant). The punch biopsies
and the original specimens were then fixed in formalin and sent for routine histological assessment.
The mean time from excision to fixation was 2 h 35 min for the first protocol and 33 min for the second
laboratory protocol.
The laboratory protocol was changed after seven samples were analysed, so that lectin incubation
was immediately performed after resection, washed to remove excess lectin then and fixed in formalin
for 24 h and immersed in ethanol. Freshly excised tissue samples were pinned onto a specimen card and
incubated with fluorescein-labelled WGA lectin for up to 15 min at room temperature and then washed
with cold buffer (to remove any excess unbound lectin). Samples were then fixed in formalin for 24 h
and then immersed in 70% ethanol. Specimens were imaged and analysed whole (i.e., no biopsies
were taken).
Each specimen was pinned under a Fluobeam® 800 camera and imaged using near-infrared
fluorescent and visible light. Samples were then sent for routine histological assessment. In addition,
at the time of sectioning for the reading of histopathology (prior to H&E staining), one extra section
was taken at each level, slide-mounted and left unstained. These slides were fluorescence imaged and
compared (overlaid) to the corresponding H&E stained slides.
4.5.2. Quantification of NIR Fluorescence Signal for Imaging Data
The NIR fluorescence signal was quantified for regions of interest (ROI) as the mean lectin
fluorescence intensity (MFI), following the subtraction of the background fluorescence. An average
MFI was calculated to produce a single score for analysis for: (i) areas of CIN3 as demarcated by
the histopathology grid overlay; (ii) each biopsy according to histopathology; (iii) whole specimens
(according to overall specimen histology). MFI was standardised for exposure time, light intensity and
distance to imaging.
4.6. Analysis
The Wilcoxon rank sum test was used to compare lectin staining in normal epithelium versus
CIN3, which was determined by comparison with an adjacent H&E stained section.
Concordance for inter-rater agreement for lectin staining was assessed using the weighted
Cohen’s kappa.
The Student’s t test with Welch’s correction for unequal variances was used to compare mean
fluorescence for comparing regions of interest within whole specimen ex vivo samples. Pairwise
comparison of CIN3 versus normal cervix biopsies was performed using the two-tailed Wilcoxon
matched-pairs signed rank test.
All statistical analyses were performed using Statistical Software: Release 16. StataCorp, 2019
(College Station, TX, USA: StataCorp LP). A p value of less than 0.05 was considered statistically
significant. All statistical tests were two-sided.
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5. Conclusions
As imaging probes, lectins are particularly appealing because their binding specificities are well
characterized, they are widely available, relatively cheap and often have low toxicities (if applied
topically). To our knowledge, this is the first evidence that topically applied lectins show the potential
to be developed as a visual assessment tool for cervical screening. Our findings warrant further
evaluation in an in vivo setting.
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